Besim Ogretmen to Kaplan-Meier Estimate
This is a "connection" page, showing publications Besim Ogretmen has written about Kaplan-Meier Estimate.
Connection Strength
0.111
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.086
-
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Sep 12; 122(11):1923-34.
Score: 0.025